Health Robotics today announced that it has signed an exclusive five-year strategic partnership with Grifols International S.A. for its revolutionary CytoCare Robot. The agreement enables Grifols to add CytoCare to its prior i.v.STATION(TM) contract with Health Robotics, and achieve its objective to safely, accurately and cost-effectively automate the preparation of Oncology I.V. Admixtures in Mexico, Chile, Brazil, Argentina, Uruguay, Paraguay, Bolivia, Peru, Venezuela, Colombia, Ecuador, Panama, Costa Rica, Belize, Nicaragua, El Salvador, Honduras, Guatemala, Surinam, French Guyana, and Guyana. In addition, the contract between the companies also adds Mexico to Grifols' i.v.STATION distribution and support rights after Health Robotics recently accomplished the termination of its last Devon Robotics contract.
While other companies have for many years made promises of robotic IV automation products, and even showcased marketing demonstrations of competing solutions that were supposed to exist as far back as twenty years ago, the fact remains that CytoCare is the only available solution that currently exists anywhere in the world to automatically compound and prepare ready-to-administer hazardous IV Admixtures for Oncology and other drug classes, and that has been proven to work in a "live" hospital pharmacy environment, instead of just marketing hype, sales brochures, and "staged" demonstrations at pharmaceutical trade symposiums such as ASHP and EAHP.
"We are very excited to have been chosen by Health Robotics as their exclusive CytoCare partner in Latin America, and to add one of the largest Latin American markets [Mexico] to our i.v.STATION distribution rights. CytoCare, the world's first and only robotic system designed for the safe and sterile preparation of patient-specific hazardous IV Admixtures, represents an ideal complement to our other market-leading Pharmacy Automation products. Health Robotics' two products will help our local service teams in Latin America differentiate our pharmacy solutions from both clinical and financial perspectives", stated Xavier Guix, VP of Marketing for Grifols' Hospital System Division".